Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.
Shijiazhuang Dingmin pharmaceutical Sciences Co.,Ltd
sales@dingminpharma.com
86-311-67260775
Model: 656247-18-6
vervoer: Ocean,Air,Express
Haven: Shanghai,Hangzhou
betaling Type: L/C,T/T,D/A,Paypal
Incoterm: FOB,CIF
Product name |
Nintedanib Ethanesulfonate Salt |
CAS NO. |
656247-18-6 |
Appearance |
white powder |
Category |
Pharmaceutical Raw Materials,Active Pharmaceutical Ingredients,Bulk Drugs,Fine Chemicals. |
Standard |
purity:>99% |
Shelf life |
2 years |
NINTEDANIB is het eerste FDA-goedgekeurde medicijn voor het beheer van idiopathische pulmonale fibrose (IPF), een zeldzame maar vaak dodelijke longziekte. NINTEDANIB wordt verondersteld zijn werkingsmechanisme uit te oefenen door meerdere receptor-tyrosinekinasen te remmen, met inbegrip van die welke zijn betrokken bij de pathogenese van IPF (dwz fibroblast groeifactorreceptor, bloedplaatjes afgeleide groeifactorreceptor en vasculaire endotheliale groeifactorreceptor). NINTEDANIB remt ook nonreceptor tyrosine kinasen, hoewel de bijdrage van deze remming in de werkzaamheid van het medicijn onbekend is.
Item |
Specification |
Results |
Appearance |
White Powder |
White Powder |
Assay |
99.0%--101.0%(Anhydrous substance) |
99.98% |
Purity |
≥99.0% |
99.89% |
Water |
≤1.0% |
0.1% |
Sulphated ash |
≤0.5% |
0.045% |
Related substances |
Unspecified impurities for each impurity |
Complies |
Heavy Metals |
≤10ppm |
<10ppm |
Loss On Drying |
≤2.0% |
0.19% |
Product Categorie : Anderen
Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.
Fill in more information so that we can get in touch with you faster
Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.